RxDoctor Payments Data

Nathaly Francois, MD

Urology · Columbia, MDNPI 1902194665

Payments from drug & device makers

$12,399in general payments, 2019–2025

Across 444 payments — averaging $27.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Teleflex LLC$1K
  • Sumitomo Pharma America, Inc.$1K
  • Neotract Inc.$1K
  • Johnson & Johnson$921
  • Bayer$668
  • plus $6K from 50 others

What the payments were for

  • Travel & lodging$2,09817%
  • Food & beverage$9,92880%
  • Education$3743%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,399 in reported general payments places this provider in the 75th percentile of 274 urology providers in Maryland.

See all urology providers in Maryland

Medicare billing

Part B allowed, 2024
$265,494
Medicare patients
730
Services billed
5,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron120$87,792
MyrbetriqMirabegron86$54,036
Methenamine Hippurate113$7,273
Mirabegron ErMirabegron15$6,436
Tamsulosin Hcl206$3,585
Estradiol36$2,727
Tolterodine Tartrate ErTolterodine Tartrate15$920
Solifenacin Succinate17$876
Fesoterodine Fumarate ErFesoterodine Fumarate14$854
Finasteride60$720
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst49$644
Cephalexin92$437
NitrofurantoinNitrofurantoin Macrocrystal26$295
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim39$113
Sildenafil Citrate12$32

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$1,125$87,792120 claims
Astellas Pharma US IncMyrbetriq$359$54,03686 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 274 urology providers in Maryland.

Other urology in Columbia

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →